{"id":45097,"date":"2024-01-07T21:49:05","date_gmt":"2024-01-07T21:49:05","guid":{"rendered":"https:\/\/news.pakistaninewspaperlist.com\/analyst-says-acelyrin-slrn-dosing-errors-create-too-much-uncertainty-securities-class-action-pending-hagens-berman\/"},"modified":"2024-01-07T21:49:05","modified_gmt":"2024-01-07T21:49:05","slug":"analyst-says-acelyrin-slrn-dosing-errors-create-too-much-uncertainty-securities-class-action-pending-hagens-berman","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/analyst-says-acelyrin-slrn-dosing-errors-create-too-much-uncertainty-securities-class-action-pending-hagens-berman\/","title":{"rendered":"Analyst Says Acelyrin (SLRN) Dosing Errors Create \u201cToo Much Uncertainty,\u201d Securities Class Action Pending &#8211; Hagens Berman"},"content":{"rendered":"<div id=\"main-body-container\" itemprop=\"articleBody\">\n<p align=\"left\">SAN FRANCISCO, Jan.  07, 2024  (GLOBE NEWSWIRE) &#8212; Hagens Berman urges Acelyrin, Inc. <strong>(NASDAQ: SLRN) <\/strong>investors who suffered substantial losses to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_66NA4d4amveY229ryFnAgR298NzUCgLKVhPgU9YW4JS3maX3OCYRrP6ViqOCYGidNG0JhQn9mdADzklPqx4njJ6Rylv-GXZ9U-rqIELdyRMVp_sJQUjP3o1nvAr2z4P\" rel=\"nofollow noopener\" target=\"_blank\" title=\"submit your losses now\">submit your losses now<\/a>.<\/p>\n<p><strong>Class Period: <\/strong>May 4, 2023 \u2013 Sept. 11, 2023<br \/><strong>Lead Plaintiff Deadline: <\/strong>Jan. 16, 2024<br \/><strong>Visit<\/strong>: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5pSxtx9q0qYSHIK-_t06CHbHGQ_WJnq4VFwbiMItDQpmcf2R09JOZoLIe_Es3hobnet0-3LxkcT9_NvRzdq1NourwfZDq32tzldC65k18IhwofcA70_m7ABaNpAc0_Pd5UDZRfCyZRQeFcbGHfRJig==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.hbsslaw.com\/investor-fraud\/SLRN\">www.hbsslaw.com\/investor-fraud\/SLRN<\/a> <br \/><strong>Contact An Attorney Now<\/strong>: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2uY4zLXRxMHPxmoE6Plu9ZGjCkf99W_qRavYGo6Tqqc7KJB0uBiy3zd2QXn3xiPyBKVDncwKpn_c-XylNIGQ6w==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"SLRN@hbsslaw.com\">SLRN@hbsslaw.com<\/a> <br \/>\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 844-916-0895<\/strong><\/p>\n<p><strong>Acelyrin, Inc. (NASDAQ: SLRN) Securities Fraud Class Action: <\/strong><\/p>\n<p>On Dec. 12, 2023, Wells Fargo\u2019s Derek Archila recently slammed Acelyrin (SLRN), writing that there is \u201ctoo much uncertainty to get involved right now\u201d and \u201cdosing errors in izokibep\u2019s Ph2\/3 trials creates uncertainty.\u201d<\/p>\n<p>The analyst criticism follows the filing of a securities class action lawsuit against Acelyrin and its top executives. That complaint alleges that Acelyrin mispresented and omitted to disclose that: (1) izokibep was less effective in treating HS than the company had led investors to believe; (2) accordingly, Acelyrin overstated izokibep\u2019s clinical and\/or commercial prospects; and (3) as a result, Acelyrin had overstated its business prospects.<\/p>\n<p>The truth emerged on Sept. 11, 2023, when Acelyrin announced disappointing top-line results from Part B of the Phase 2b\/3 trial evaluating izokibep for the treatment of moderate to severe HS. The company said izokibep was unable to significantly outperform placebo in terms of 16-week HiSCR75 score, a measure that represents at least a 75% reduction in disease markers.<\/p>\n<p>Two weeks after the filing of the suit, on Nov. 27, 2023, Acelyrin announced that it will be conducting a comprehensive review of the development program for izokibep after it discovered critical dosing errors committed by contract research organization (CRO) Fortrea.<\/p>\n<p>The clinical trial \u201cexecution errors\u201d Acelyrin disclosed two weeks after the securities suit was filed purportedly affected a psoriatic arthritis trial of izokibep. According to Acelyrin, a vendor engaged by the CRO had incorrectly programmed the proper dosing sequence, an error that further went undetected during the testing process.<\/p>\n<p>As a result of the CRO and the vendor\u2019s oversight, \u201csome patients in the 160mg Q2W and 80mg Q4W arms received placebo and active treatment in random order rather than in an alternating pattern as intended,\u201d Acelyrin stated.<\/p>\n<p>Acelyrin\u2019s shares have lost nearly 70% of their value year to date.<\/p>\n<p>\u201cWe are investigating whether Acelyrin may have known of but did not disclose the critical dosing errors, and if so, whether the alleged fraudulent period should be extended,\u201d said Reed Kathrein, the Hagens Berman partner leading the investigation.<\/p>\n<p>If you invested in Acelyrin and have substantial losses, or have knowledge that may assist the firm\u2019s investigation, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_66NA4d4amveY229ryFnAgR298NzUCgLKVhPgU9YW4IPg29CBkZILdz1i2195sgCjsBQfVV-M8qpXs8iL8ZQOYFlzD64d-ORptPL47oQ5vHNXb-UQ34RFim_yoHg8yQg\" rel=\"nofollow noopener\" target=\"_blank\" title=\"submit your losses now\">submit your losses now<\/a> \u00bb<\/p>\n<p>If you\u2019d like more information and answers to frequently asked questions about the Acelyrin case and our investigation, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Pxgf6vFCrzzldV_I5aTy6exHRFke5iT8tCdW9xeRKkMWaxrOXL5OUAH3MNCUk_QrWCu3BIZDaV-G_cmV-bmbPYYHBrlyxSNnJaW1OERqE1raAjoMahC9SFDuDReamTtKrxQTK6RnQagFNCbYYEhJtw==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"read more\">read more<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-pJBX-lWeORE4QsndHWi2D5wTfFwJUxUsbi4GtO-kNYwueQrLAeaz1eFmpStm6tHbhJFDRFkF9aVGu5HD5G8JZeNaNNNHxnq7QcWutWffktwnI4dFg9AsKZfTPoj46meBTcucdh-aSl19HejXUvbJg==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\u00bb\"> \u00bb<\/a><\/p>\n<p><strong>Whistleblowers: <\/strong>Persons with non-public information regarding Acelyrin should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at <strong>844-916-0895<\/strong> or email <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2uY4zLXRxMHPxmoE6Plu9TY_vn3B5QserW4vNLITBGJMnCcm4V5CfEhgKjfFunprn8XfN9GSOABLaonapFmycg==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"SLRN@hbsslaw.com\">SLRN@hbsslaw.com<\/a>.<\/p>\n<p><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YhWcMElQFHDXXg2coMIDsreTGvfFoR42YCgziwP_kSV_mFD0bcAo4TUaSP0EN3_2q6HMOA_VcXzA7E52JBaQbA8K9h6czo7RIFpL0QngOjs=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"About Hagens Berman\">About Hagens Berman<\/a><br \/>Hagens Berman is a global plaintiffs\u2019 rights complex litigation law firm focusing on corporate accountability through class-action law. The firm is home to a robust securities litigation practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and fraud. More about the firm and its successes can be found at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pF_ujQU_3sv3Ir0rWsJVordOKPSd5yPnOCW9XZ97ppG_iub1RuQ3WZRhAGncR1pTZOGkMPWcbkvV6CxLzIkcaA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"hbsslaw.com\">hbsslaw.com<\/a>. Follow the firm for updates and news at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K-aFIpjgm0FHJAw3EjKmxAPl4iBj3fAwqGSv8zPkgP8C0MNJ664-IoDolD8jwVlO7KBIyqLRJ8IwNkPSEZ6ywhDN7V83kgSEEZJiSHu_OlQ=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"@ClassActionLaw\">@ClassActionLaw<\/a>.\u00a0<\/p>\n<p><strong>Attorney advertising.<\/strong><br \/><strong>Past results do not guarantee future outcomes.<\/strong><br \/><strong>Services may be performed by attorneys in any of our offices<\/strong>.\u00a0<\/p>\n<p><u>Contact: <\/u><br \/>Reed Kathrein, 844-916-0895<\/p>\n<p>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN FRANCISCO, Jan. 07, 2024 (GLOBE NEWSWIRE) &#8212; Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 \u2013 Sept. 11, 2023Lead Plaintiff Deadline: Jan. 16, 2024Visit: www.hbsslaw.com\/investor-fraud\/SLRN Contact An Attorney Now: SLRN@hbsslaw.com \u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 844-916-0895 Acelyrin, Inc. [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":45098,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/51670c91-d369-4a8c-8102-d393de9f6d19","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-45097","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/45097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=45097"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/45097\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/45098"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=45097"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=45097"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=45097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}